Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia

Reuters03-26 20:31

Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia

Neurocrine reported that expert consensus recommendations on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings were presented at the PALTmed PALTC26 Annual Conference.
A post-hoc analysis from the Phase 4 KINECT-PRO study was also presented, evaluating patient-reported outcomes with once-daily Ingrezza (valbenazine) in adults age 65 and older.
The analysis reported improvements at Week 24 in tardive dyskinesia symptoms, quality of life, and functional impairment, based on multiple validated scales including the Tardive Dyskinesia Impact Scale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA19667) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622717857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622717857","market":"nz","top_or_hot":-1,"title":"Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Neurocrine reported that expert consensus recommendations on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings were presented at the PALTmed PALTC26 Annual Conference.\n        </li>\n<li>\n          A post-hoc analysis from the Phase 4 KINECT-PRO study was also presented, evaluating patient-reported outcomes with once-daily Ingrezza (valbenazine) in adults age 65 and older.\n        </li>\n<li>\n          The analysis reported improvements at Week 24 in tardive dyskinesia symptoms, quality of life, and functional impairment, based on multiple validated scales including the Tardive Dyskinesia Impact Scale.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA19667) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Neurocrine reported that expert consensus recommendations on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings were presented at the PALTmed PALTC26 Annual Conference.\n        </li>\n<li>\n          A post-hoc analysis from the Phase 4 KINECT-PRO study was also presented, evaluating patient-reported outcomes with once-daily Ingrezza (valbenazine) in adults age 65 and older.\n        </li>\n<li>\n          The analysis reported improvements at Week 24 in tardive dyskinesia symptoms, quality of life, and functional impairment, based on multiple validated scales including the Tardive Dyskinesia Impact Scale.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA19667) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLcfrf6t:1","article_id":"2622717857","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622717857","pubTimestamp":1774528285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia. Neurocrine reported that expert consensus recommendations on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings were presented at the PALTmed PALTC26 Annual Conference.A post-hoc analysis from the Phase 4 KINECT-PRO study was also presented, evaluating patient-reported outcomes with once-daily Ingrezza  in adults age 65 and older.The analysis reported improvements at Week 24 in tardive dyskinesia symptoms, quality of life, and functional impairment, based on multiple validated scales including the Tardive Dyskinesia Impact Scale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","NBIX":"神经分泌生物科学","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC"},"translate_title":"Neurocrine Biosciences展示事后KINECT-PRO分析；INGREZZA在患有迟发性运动障碍的65岁以上成人中显示出第24周具有临床意义的TDIS改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":0.9},"content_text":"Neurocrine Biosciences presents post-hoc KINECT-PRO analysis; INGREZZA shows clinically meaningful TDIS improvements at Week 24 in adults 65+ with tardive dyskinesia\n    \n\n\n          Neurocrine reported that expert consensus recommendations on screening, diagnosis, and treatment of tardive dyskinesia in long-term care settings were presented at the PALTmed PALTC26 Annual Conference.\n        \n\n          A post-hoc analysis from the Phase 4 KINECT-PRO study was also presented, evaluating patient-reported outcomes with once-daily Ingrezza (valbenazine) in adults age 65 and older.\n        \n\n          The analysis reported improvements at Week 24 in tardive dyskinesia symptoms, quality of life, and functional impairment, based on multiple validated scales including the Tardive Dyskinesia Impact Scale.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA19667) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622717857","isCrawlerRequest":true}